Addendum
Olaparib (ovarian cancer; first-line maintenance in combination with bevacizumab) - Addendum to Commission A20-111
Report documents
-
Addendum
Olaparib (ovarian cancer; first-line maintenance in combination with bevacizumab) - Addendum to Commission A20-111
Dossier assessment
Maintenance therapy of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose tumour is associated with HRD-positive status
Patients without detectable tumour after primary surgery and patients without detectable tumour/with complete response following chemotherapy: indication of considerable added benefit.
Patients without detectable tumour after interval surgery and patients with partial response: indication of lesser benefit.
Additional information
Federal Joint Committee (G-BA)
2021.06.04 A G-BA decision was published.
Project details
- Project no.
- A21-55
- Commission
- Commission awarded on 28.04.2021 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Olaparib (ovarian cancer; first-line maintenance in combination with bevacizumab) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed